Grazia D'Onofrio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5222345/publications.pdf

Version: 2024-02-01

93 papers 2,887 citations

33 h-index 197818 49 g-index

94 all docs 94 docs citations

times ranked

94

4472 citing authors

#	Article	IF	CITATIONS
1	Knowledge Engineering Framework for IoT Robotics Applied to Smart Healthcare and Emotional Well-Being. International Journal of Social Robotics, 2023, 15, 445-472.	4.6	7
2	User Profiling to Enhance Clinical Assessment and Human–Robot Interaction: A Feasibility Study. International Journal of Social Robotics, 2023, 15, 501-516.	4.6	3
3	Involving Older Adults During COVID-19 Restrictions in Developing an Ecosystem Supporting Active Aging: Overview of Alternative Elicitation Methods and Common Requirements From Five European Countries. Frontiers in Psychology, 2022, 13, 818706.	2.1	8
4	Emotion Recognizing by a Robotic Solution Initiative (EMOTIVE Project). Sensors, 2022, 22, 2861.	3.8	9
5	Pilots for Healthy and Active Ageing (PHArA-ON) Project: Definition of New Technological Solutions for Older People in Italian Pilot Sites Based on Elicited User Needs. Sensors, 2022, 22, 163.	3.8	9
6	Internet-Based Psychological Interventions during SARS-CoV-2 Pandemic: An Experience in South of Italy. International Journal of Environmental Research and Public Health, 2022, 19, 5425.	2.6	3
7	Psychological Interventions in a Pandemic Emergency: A Systematic Review and Meta-Analysis of SARS-CoV-2 Studies. Journal of Clinical Medicine, 2022, 11, 3209.	2.4	6
8	CT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment. Biomedicines, 2022, 10, 1381.	3.2	0
9	Assistive robots to improve the independent living of older persons: results from a needs study. Disability and Rehabilitation: Assistive Technology, 2021, 16, 92-102.	2.2	40
10	Relationship of Homocysteine Plasma Levels with Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia, Psychobehavioral, and Functional Complications. Journal of Alzheimer's Disease, 2021, 82, 235-248.	2.6	17
11	Crocus Sativus L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment. Current Neuropharmacology, 2021, 19, 1606-1616.	2.9	11
12	Enteral tube feeding and mortality in hospitalized older patients: A multicenter longitudinal study. Clinical Nutrition, 2020, 39, 1608-1612.	5.0	9
13	Co-creation of an assistive robot for independent living: lessons learned on robot design. International Journal on Interactive Design and Manufacturing, 2020, 14, 491-502.	2.2	16
14	Oral microbiota and Alzheimer's disease: Do all roads lead to Rome?. Pharmacological Research, 2020, 151, 104582.	7.1	79
15	Dialogue Systems and Conversational Agents for Patients with Dementia: The Human–Robot Interaction. Rejuvenation Research, 2019, 22, 109-120.	1.8	32
16	Treating Neuropsychiatric Symptoms of Alzheimer's disease: un update. International Journal of Geriatric Psychiatry, 2019, 34, 1285-1286.	2.7	0
17	Phosphodiesterase inhibitors say NO to Alzheimer's disease. Food and Chemical Toxicology, 2019, 134, 110822.	3.6	52
18	Insomnia and Information and Communication Technologies (ICT) in Elderly People: A Systematic Review. Medical Sciences (Basel, Switzerland), 2019, 7, 70.	2.9	7

#	Article	IF	CITATIONS
19	MARIO Project: Validation and Evidence of Service Robots for Older People with Dementia. Journal of Alzheimer's Disease, 2019, 68, 1587-1601.	2.6	33
20	Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease. Translational Neurodegeneration, 2019, 8, 4.	8.0	5
21	Assistive robots for socialization in elderly people: results pertaining to the needs of the users. Aging Clinical and Experimental Research, 2019, 31, 1313-1329.	2.9	29
22	Using the Multidimensional Prognostic Index to Predict Clinical Outcomes of Hospitalized Older Persons: A Prospective, Multicenter, International Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1643-1649.	3.6	56
23	MARIO Project: Experimentation in the Hospital Setting. Lecture Notes in Electrical Engineering, 2019, , 289-303.	0.4	4
24	ACCRA Project: Agile Co-Creation for Robots and Aging. Lecture Notes in Electrical Engineering, 2019, , 133-150.	0.4	4
25	Evaluation of a Companion Robot for Individuals With Dementia: Quantitative Findings of the MARIO Project in an Irish Residential Care Setting. Journal of Gerontological Nursing, 2019, 45, 36-45.	0.6	40
26	ViTA: Virtual Trainer for Aging. Lecture Notes in Electrical Engineering, 2019, , 199-208.	0.4	2
27	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4333-4344.	4.0	19
28	Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer's Disease Versus Vascular Dementia. Journal of Alzheimer's Disease, 2018, 62, 699-711.	2.6	17
29	Apigenin as neuroprotective agent: Of mice and men. Pharmacological Research, 2018, 128, 359-365.	7.1	135
30	Agile Co-Creation for Robots and Aging (ACCRA) Project: new technological solutions for older people. European Geriatric Medicine, 2018, 9, 795-800.	2.8	15
31	Late-Life Depression versus Amnestic Mild Cognitive Impairment: Alzheimer's Disease Incidence in 4 Years of Follow-Up. Dementia and Geriatric Cognitive Disorders, 2018, 46, 140-153.	1.5	13
32	Neurocognitive Disorders and Dehydration in Older Patients: Clinical Experience Supports the Hydromolecular Hypothesis of Dementia. Nutrients, 2018, 10, 562.	4.1	31
33	A Multicenter Survey About Companion Robot Acceptability in Caregivers of Patients with Dementia. Lecture Notes in Electrical Engineering, 2018, , 161-178.	0.4	2
34	Erythrocyte Associated Amyloid- \hat{l}^2 as Potential Biomarker to Diagnose Dementia. Current Alzheimer Research, 2018, 15, 381-385.	1.4	11
35	Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder. Molecular Neurobiology, 2017, 54, 1340-1351.	4.0	28
36	Emerging biomarkers and screening for cognitive frailty. Aging Clinical and Experimental Research, 2017, 29, 1075-1086.	2.9	39

#	Article	IF	CITATIONS
37	Robotic and Sensor Technologies for Mobility in Older People. Rejuvenation Research, 2017, 20, 401-410.	1.8	21
38	Implementation of a Solution for the Remote Monitoring of Subjects Affected of Metabolic Diseases: The Metabolink Project. Lecture Notes in Electrical Engineering, 2017, , 191-196.	0.4	1
39	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. Expert Opinion on Drug Safety, 2017, 16, 1373-1385.	2.4	8
40	Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2017, 57, 927-935.	2.6	60
41	Sexual dimorphism of frailty and cognitive impairment: Potential underlying mechanisms. Molecular Medicine Reports, 2017, 16, 3023-3033.	2.4	18
42	From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention. , 2017, , .		4
43	Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review. Current Drug Targets, 2017, 18, 1487-1498.	2.1	38
44	MARIO Project: A Multicenter Survey About Companion Robot Acceptability in Caregivers of Patients with Dementia. Lecture Notes in Electrical Engineering, 2017, , 311-336.	0.4	6
45	Daidzein and its Effects on Brain. Current Medicinal Chemistry, 2017, 24, 365-375.	2.4	33
46	Design and Evaluation of an ICT Platform for Cognitive Stimulation of Alzheimer's Disease Patients. Lecture Notes of the Institute for Computer Sciences, Social-Informatics and Telecommunications Engineering, 2017, , 106-115.	0.3	1
47	Alzheimer's Disease and Cognitive Frailty: Novel Therapeutic Technologies. BioMed Research International, 2016, 2016, 1-2.	1.9	0
48	Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach. Journal of Alzheimer's Disease, 2016, 51, 427-437.	2.6	26
49	Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1368-1374.	1.9	36
50	Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. BMC Geriatrics, 2016, 16, 104.	2.7	59
51	Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty. Molecular Medicine Reports, 2016, 14, 3184-3198.	2.4	16
52	Neuroprotective Effects of Quercetin: From Chemistry to Medicine. CNS and Neurological Disorders - Drug Targets, 2016, 15, 964-975.	1.4	48
53	A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2015, 30, 965-975.	2.7	34
54	Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. Journal of Psychopharmacology, 2015, 29, 623-633.	4.0	18

#	Article	IF	Citations
55	Caregiver burden characterization in patients with Alzheimer's disease or vascular dementia. International Journal of Geriatric Psychiatry, 2015, 30, 891-899.	2.7	61
56	FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. Clinical Interventions in Aging, 2014, 9, 1783.	2.9	13
57	Cognitive Home Rehabilitation in Alzheimer's Disease Patients by a Virtual Personal Trainer. , 2014, , 147-155.		6
58	The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2013, 21, 67-77.	1.2	8
59	Neuropsychiatric Symptoms and Functional Status in Alzheimer's Disease and Vascular Dementia Patients. Current Alzheimer Research, 2012, 9, 759-771.	1.4	75
60	Treatment of Late-Life Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors Improves the Multidimensional Prognostic Index. Journal of Clinical Psychopharmacology, 2012, 32, 726-729.	1.4	20
61	Advances in the identification of \hat{I}^3 -secretase inhibitors for the treatment of Alzheimer's disease. Expert Opinion on Drug Discovery, 2012, 7, 19-37.	5.0	45
62	Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis. Age, 2012, 34, 949-968.	3.0	8
63	TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2012, 31, 731-740.	2.6	20
64	Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. Ageing Research Reviews, 2012, 11, 87-103.	10.9	57
65	A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. Journal of Neurology, 2012, 259, 670-678.	3.6	46
66	Pharmacogenetics in older people: what we know and what we need to know. Journal of Nephrology, 2012, 25, 38-47.	2.0	10
67	Therapeutic intervention for Alzheimer's disease with \hat{I}^3 -secretase inhibitors: still a viable option?. Expert Opinion on Investigational Drugs, 2011, 20, 325-341.	4.1	86
68	The Genetics of the Human APOE Polymorphism. Rejuvenation Research, 2011, 14, 491-500.	1.8	81
69	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	2.0	18
70	Mediterranean Diet in Predementia and Dementia Syndromes. Current Alzheimer Research, 2011, 8, 520-542.	1.4	73
71	Information and Communication Technology Systems to Improve Quality of Life and Safety of Alzheimer's Disease Patients: A Multicenter International Survey. Journal of Alzheimer's Disease, 2011, 23, 131-141.	2.6	52
72	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenetics and Genomics, 2011, 21, 225-230.	1.5	62

#	Article	IF	CITATIONS
73	Validation of a modified-multidimensional prognostic index (m-MPI) including the mini nutritional assessment short-form (MNA-SF) for the prediction of one-year mortality in hospitalized elderly patients. Journal of Nutrition, Health and Aging, 2011, 15, 169-173.	3.3	62
74	Different models of frailty in predementia and dementia syndromes. Journal of Nutrition, Health and Aging, 2011, 15, 711-719.	3.3	76
75	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. Age, 2011, 33, 409-419.	3.0	6
76	The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes. International Journal of Geriatric Psychiatry, 2011, 26, 1062-1070.	2.7	27
77	Metabolic Syndrome, Mild Cognitive Impairment and Dementia. Current Alzheimer Research, 2011, 8, 492-509.	1.4	67
78	Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab. Current Alzheimer Research, 2011, 8, 808-817.	1.4	51
79	Statistical parametric mapping of FDG-PET in Alzheimer disease. , 2011, , .		2
80	Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clinical Laboratory, 2011, 57, 887-93.	0.5	13
81	Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms. Journal of Alzheimer's Disease, 2010, 21, 691-724.	2.6	139
82	Apolipoprotein E-related all-cause mortality in hospitalized elderly patients. Age, 2010, 32, 411-420.	3.0	5
83	Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2010, 29, 424-431.	1.5	6
84	Bapineuzumab: anti- \hat{l}^2 -amyloid monoclonal antibodies for the treatment of Alzheimer $\hat{a} \in \mathbb{N}$ s disease. Immunotherapy, 2010, 2, 767-782.	2.0	52
85	The Multidimensional Prognostic Index (MPI), Based on a Comprehensive Geriatric Assessment Predicts Short- and Long-Term Mortality in Hospitalized Older Patients with Dementia. Journal of Alzheimer's Disease, 2009, 18, 191-199.	2.6	77
86	The Multidimensional Prognostic Index Predicts Short- and Long-Term Mortality in Hospitalized Geriatric Patients With Pneumonia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 880-887.	3.6	78
87	Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73, 761-767.	1.1	102
88	The Comprehensive Geriatric Assessment and the multidimensional approach. A new look at the older patient with gastroenterological disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 829-837.	2.4	41
89	Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease. Ageing Research Reviews, 2009, 8, 214-236.	10.9	46
90	Association of Apolipoprotein E and Angiotensin Converting Enzyme Gene Polymorphisms with the Multidimensional Impairment in Older Patients. Rejuvenation Research, 2009, 12, 239-247.	1.8	6

GRAZIA D'ONOFRIO

#	Article	IF	CITATIONS
91	Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. Neuroscience Letters, 2008, 438, 335-339.	2.1	10
92	The RELN Locus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 335-344.	2.6	56
93	Non-Pharmacological Approaches in the Treatment of Dementia. , 0, , .		3